WebJan 27, 2024 · Bristol-Myers Squibb (BMY 0.49%) reported very good fourth-quarter results on Thursday. Revenue jumped 10% year over year, with strong growth for blockbuster drugs Opdivo and Eliquis leading the way. WebQ4 2024 Earnings Highlights Full-Year Highlights TOTAL NET SALES $46.2B GAAP EPS 1 $2.95 Non-GAAP EPS 1,2 $7.70 Fourth Quarter Highlights TOTAL NET SALES $11.4B …
What To Expect From Bristol Myers Squibb’s Q4? - Forbes
WebApr 11, 2024 · Transcript : Bristol-Myers Squibb Company, Q4 2024 Earnings Call, Feb 04, 2024. Good day, everyone, and welcome to the Bristol-Myers Squibb 2024 Fourth Quarter Results Conference Call. Today's conference is being recorded. At this time, I'd like to turn the call over to Mr.... WebFeb 2, 2024 · • The earnings report was released just over a week after Takeda announced it acquired the rights to develop and commercialize Hutchmed’s experimental cancer drug Fruquintinib outside of mainland China, Hong Kong and Macau. BMS: • Like Lilly, BMS reported a revenue miss in Q4, with revenues down by about $500 million year-over-year. forgehill park workington
Bristol-Myers (BMY) to Post Q4 Earnings: What
WebFeb 2, 2024 · Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.83 per share a year ago. WebFeb 4, 2024 · NYSE: BMY Bristol-Myers Squibb Market Cap $145B Today's Change (0.16%) $0.11 Current Price $69.30 Price as of March 3, 2024, 4:00 p.m. ET BMY … WebJul 28, 2024 · Bristol Myers Squibb Reports Second Quarter Financial Results for 2024. Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange. Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93. Delivers Strong Commercial Performance, Including … difference between anatomist and physiologist